Previous 10 | Next 10 |
home / stock / bmy / bmy articles
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the “Fear” ...
Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.5...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling by around 100 points on Thursday. The Dow traded down 1.20% t...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Shares of Swiss pharma giant Novartis AG (NYSE:NVS) after the company raised its full-year guidance following better-than-expected first-quarter...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
Friday, Agenus Inc (NASDAQ:AGEN) released updated results from its Phase 1 clinical trial of botensilimab and balstilimab (BOT/BAL) combi...
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) a...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...